Patents by Inventor Joseph Kushner, IV

Joseph Kushner, IV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20220142927
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 11253523
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20200206232
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 10639309
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 9937181
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 10, 2018
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20140271842
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock